Repligen reported strong second-quarter 2026 results marked by revenue growth and margin expansion, underpinning its core bioprocessing franchise. The company announced a $1.5 billion acquisition of BioLife Solutions to broaden its cell therapy capabilities, signaling a deliberate pivot toward the higher-growth cell therapy segment. While liquidity remains robust, successful integration of BioLife represents a critical execution challenge and pivotal factor for realizing expected synergies and market expansion. Repligen’s position as an essential bioprocessing supplier is supported by increasing adoption of single-use technologies and rising biologic drug manufacturing demand.